Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.01.2023 | Case report

Bedaquiline/clofazimine/levofloxacin

QT corrected interval prolongation: 18 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Isralls S, et al. QT Interval Prolongation in People Treated with Bedaquiline for Drug-Resistant Tuberculosis under Programmatic Conditions: A Retrospective Cohort Study. Open Forum Infectious Diseases 8: 1-10, No. 8, Aug 2021. Available from: URL: http://doi.org/10.1093/ofid/ofab413 Isralls S, et al. QT Interval Prolongation in People Treated with Bedaquiline for Drug-Resistant Tuberculosis under Programmatic Conditions: A Retrospective Cohort Study. Open Forum Infectious Diseases 8: 1-10, No. 8, Aug 2021. Available from: URL: http://​doi.​org/​10.​1093/​ofid/​ofab413
Metadaten
Titel
Bedaquiline/clofazimine/levofloxacin
QT corrected interval prolongation: 18 case reports
Publikationsdatum
01.01.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-30452-0

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Heparin

Case report

Tozinameran

Case report

Ciclosporin

Case report

Ascorbic-acid

Case report

Multiple drugs